Objective: To analyse the performance of a new M tuberculosis-specific interferon γ (IFNγ) assay in patients with chronic inflammatory diseases who receive immunosuppressive drugs, including tumour necrosis factor α (TNFα) inhibitors.
Methods: Cellular immune responses to the M tuberculosis-specific antigens ESAT-6, CFP-10, TB7.7 were prospectively studied in 142 consecutive patients treated for inflammatory rheumatic conditions. Results were compared with tuberculin skin tests (TSTs). Association of both tests with risk factors for latent M tuberculosis infection (LTBI) and BCG vaccination were determined and the influence of TNFα inhibitors, corticosteroids, and disease modifying antirheumatic drugs (DMARDs) on antigen-specific and mitogen-induced IFNγ secretion was analysed.
Results: 126/142 (89%) patients received immunosuppressive therapy. The IFNγ assay was more closely associated with the presence of risk factors (odds ratio (OR) = 23.8 (95% CI 5.14 to 110) vs OR = 2.77 (1.22 to 6.27), respectively; p = 0.009), but less associated with BCG vaccination than the TST (OR = 0.47 (95% CI 0.15 to 1.47) vs OR = 2.44 (0.74 to (8.01), respectively; p = 0.025). Agreement between the IFNγ assay and TST results was low (κ = 0.17; 95% CI 0.02 to 0.32). The odds for a positive IFNγ assay strongly increased with increasing prognostic relevance of LTBI risk factors. Neither corticosteroids nor conventional DMARDs significantly affected IFNγ responses, but the odds for a positive IFNγ assay were decreased in patients treated with TNFα inhibitors (OR = 0.21 (95% CI 0.07 to 0.63), respectively; p = 0.006).
Conclusions: These results demonstrate that the performance of the M tuberculosis antigen-specific IFNγ ELISA is better than the classic TST for detection of LTBI in patients receiving immunosuppressive therapy for treatment of systemic autoimmune disorders.
Statistics from Altmetric.com
Competing interests: None.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.